The ups and downs of drug discovery: the early history of Fidaxomicin.
The path from antibiotic compound discovery to the market is marked by many potholes and its negotiation is often dependent on luck and persistence. Perhaps the prime example of this is the case of the development of tiacumicin B to Fidaxomicin, where both parameters were critical and the path was particularly circuitous.